131 related articles for article (PubMed ID: 16958135)
21. Strategies for hepatitis C therapeutic intervention: now and next.
Tan SL; He Y; Huang Y; Gale M
Curr Opin Pharmacol; 2004 Oct; 4(5):465-70. PubMed ID: 15351350
[TBL] [Abstract][Full Text] [Related]
22. Novel insights into hepatitis C virus replication and persistence.
Bartenschlager R; Frese M; Pietschmann T
Adv Virus Res; 2004; 63():71-180. PubMed ID: 15530561
[TBL] [Abstract][Full Text] [Related]
23. [Overview of hepatitis C virus from its discovery to now].
Inoue K; Yoshiba M
Rinsho Byori; 2001 Aug; 49(8):733-40. PubMed ID: 11573279
[TBL] [Abstract][Full Text] [Related]
24. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy.
Sakamoto H; Okamoto K; Aoki M; Kato H; Katsume A; Ohta A; Tsukuda T; Shimma N; Aoki Y; Arisawa M; Kohara M; Sudoh M
Nat Chem Biol; 2005 Nov; 1(6):333-7. PubMed ID: 16408072
[TBL] [Abstract][Full Text] [Related]
25. Molecular biology of hepatitis C infection.
Drazan KE
Liver Transpl; 2000 Jul; 6(4):396-406. PubMed ID: 10915159
[TBL] [Abstract][Full Text] [Related]
26. Development of prophylactic and therapeutic vaccines against hepatitis C virus.
Leroux-Roels G
Expert Rev Vaccines; 2005 Jun; 4(3):351-71. PubMed ID: 16026249
[TBL] [Abstract][Full Text] [Related]
27. [Immune evasion mechanisms of hepatitis C virus. Review].
Porto-Espinoza L; Cuadra-Sánchez C; Moronta R; Monsalve-Castillo F; Callejas-Valero D
Invest Clin; 2006 Mar; 47(1):71-82. PubMed ID: 16562646
[TBL] [Abstract][Full Text] [Related]
28. Evasion of intracellular host defence by hepatitis C virus.
Gale M; Foy EM
Nature; 2005 Aug; 436(7053):939-45. PubMed ID: 16107833
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus: Enslavement of host factors.
Sharma G; Raheja H; Das S
IUBMB Life; 2018 Jan; 70(1):41-49. PubMed ID: 29281185
[TBL] [Abstract][Full Text] [Related]
30. New therapies on the horizon for hepatitis C.
Sookoian SC
Ann Hepatol; 2003; 2(4):164-70. PubMed ID: 15115955
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection.
Tang J; Kaslow RA
Pharmacogenomics J; 2004; 4(3):171-4. PubMed ID: 15069460
[No Abstract] [Full Text] [Related]
32. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.
Ploss A; Dubuisson J
Gut; 2012 May; 61 Suppl 1():i25-35. PubMed ID: 22504917
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms involved in the development of chronic hepatitis C as potential targets of antiviral therapy.
Jackowiak P; Figlerowicz M; Kurzyńska-Kokorniak A; Figlerowicz M
Curr Pharm Biotechnol; 2011 Nov; 12(11):1774-80. PubMed ID: 21902631
[TBL] [Abstract][Full Text] [Related]
34. Drug abuse, innate immunity and hepatitis C virus.
Zhang T; Li Y; Ho WZ
Rev Med Virol; 2006; 16(5):311-27. PubMed ID: 16933366
[TBL] [Abstract][Full Text] [Related]
35. Evolution of efficacious pangenotypic hepatitis C virus therapies.
Ashraf MU; Iman K; Khalid MF; Salman HM; Shafi T; Rafi M; Javaid N; Hussain R; Ahmad F; Shahzad-Ul-Hussan S; Mirza S; Shafiq M; Afzal S; Hamera S; Anwar S; Qazi R; Idrees M; Qureshi SA; Chaudhary SU
Med Res Rev; 2019 May; 39(3):1091-1136. PubMed ID: 30506705
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C therapeutics: current status and emerging strategies.
Tan SL; Pause A; Shi Y; Sonenberg N
Nat Rev Drug Discov; 2002 Nov; 1(11):867-81. PubMed ID: 12415247
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of chronic hepatitis C and molecular biology tests].
Córdoba Cortijo J; Molina Moreno JM
Rev Esp Quimioter; 2005 Sep; 18(3):207-9. PubMed ID: 16369661
[No Abstract] [Full Text] [Related]
38. Treating hepatitis C infection by targeting the host.
Salloum S; Tai AW
Transl Res; 2012 Jun; 159(6):421-9. PubMed ID: 22633094
[TBL] [Abstract][Full Text] [Related]
39. Overcoming the roadblocks in hepatitis C virus infection.
Baumert TF; Zeuzem S
J Hepatol; 2014 Nov; 61(1 Suppl):S1-2. PubMed ID: 25443338
[No Abstract] [Full Text] [Related]
40. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.
Pawlotsky JM; McHutchison JG
Hepatology; 2004 Feb; 39(2):554-67. PubMed ID: 14768012
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
